Patents by Inventor Chun Kwong Chu
Chun Kwong Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210244651Abstract: An anti-wrinkle cosmetic composition comprises a Kava extract, one or more penetration and other anti-wrinkle agents. The Kava extract is extracted from Piper Methysticum root, leaf, stem, or their combinations.Type: ApplicationFiled: June 5, 2019Publication date: August 12, 2021Applicant: NAL PHARMACEUTICAL GROUP LIMITEDInventor: Chun Kwong CHU
-
Patent number: 10682370Abstract: The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV).Type: GrantFiled: March 12, 2014Date of Patent: June 16, 2020Assignee: NAL PHARMACEUTICAL GROUP LIMITEDInventors: Je Phil Ryoo, Chun Kwong Chu
-
Patent number: 9579295Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: July 20, 2015Date of Patent: February 28, 2017Assignee: NAL PHARMACEUTICAL GROUP LIMITEDInventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20170002057Abstract: The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum albumin or a region with a partial amino acid sequence of human serum albumin, wherein linker peptide sequences may be present between somatostatin and somatostatin moieties or somatostatin and albumin moieties. Also disclosed are constructs wherein the somatostatin moiety contains multiple tandem repeats of a somatostatin sequence. In selected embodiments, the orientation of the somatostatin and albumin moieties can be varied, and such sequences may impact the binding and efficacy of the disclosed fusion proteins. Also disclosed are methods of making and using the aforementioned constructs. The somatostatin-albumin fusion protein demonstrated enhanced stability when incubated in rat plasma in vitro and prolonged plasma half-life in vivo compared with free somatostatin.Type: ApplicationFiled: August 26, 2016Publication date: January 5, 2017Applicant: NAL PHARMACEUTICAL GROUP LIMITEDInventors: Y. Joseph MO, Chun Kwong CHU
-
Publication number: 20160015731Abstract: The present invention provides a novel pharmaceutical composition and method of making the same. The composition comprises an effective amount of an antiviral agent and a local anesthetic. The antiviral drug can be sorivudine. The local anesthetic can be lidocaine or its pharmaceutically acceptable salt. Herpes virus infections in humans can be caused by different human herpes viruses, the most common being herpes simplex virus types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV).Type: ApplicationFiled: March 12, 2014Publication date: January 21, 2016Applicant: NAL PHARMACEUTICALS, LTD.Inventors: Je Phil RYOO, Chun Kwong CHU
-
Publication number: 20150320695Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: July 20, 2015Publication date: November 12, 2015Applicant: NAL PHARMACEUTICALS LTD.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 9119776Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: June 19, 2014Date of Patent: September 1, 2015Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 9114074Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: May 16, 2014Date of Patent: August 25, 2015Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 9114073Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: May 16, 2014Date of Patent: August 25, 2015Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 9114075Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: June 19, 2014Date of Patent: August 25, 2015Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 8900634Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: March 3, 2011Date of Patent: December 2, 2014Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang, Diana Shu-Lian Chow, Roland A. Ako
-
Publication number: 20140329835Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: June 19, 2014Publication date: November 6, 2014Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20140328915Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: June 19, 2014Publication date: November 6, 2014Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20140255487Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: May 16, 2014Publication date: September 11, 2014Applicant: NAL Pharmaceuticals Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20140248353Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: NAL Pharmaceuticals Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 8771736Abstract: Oral dosage forms and methods for delivering effective amounts of erectile dysfunction medicaments to patients to provide rapid uptake of said agents through the mucosa of the oral cavity are disclosed.Type: GrantFiled: October 18, 2012Date of Patent: July 8, 2014Assignee: NAL Pharmaceuticals, Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Patent number: 8715715Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: GrantFiled: October 29, 2009Date of Patent: May 6, 2014Assignee: NAL Pharmaceuticals Ltd.Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
-
Publication number: 20110189288Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: March 3, 2011Publication date: August 4, 2011Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang, Diana Shu-Lian Chow, Roland A. Ako
-
Publication number: 20100112050Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.Type: ApplicationFiled: October 29, 2009Publication date: May 6, 2010Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang